 SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB, a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus HBV and diseases associated with the microbiome, today announced grants of stock options to three new employees to purchase an aggregate of 14,520 shares of the Companys common stock with an exercise price of 5.66 per share, the closing price of Assembly Bios common stock on December 1, 2020. The stock options were granted as material inducements to the new employees to accept the Companys offers of employment. 